Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avanos Medical (AVNS) Shares Outstanding (Weighted Average) (2016 - 2026)

Avanos Medical's Shares Outstanding (Weighted Average) history spans 13 years, with the latest figure at $46.3 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 0.65% to $46.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.3 million, a 0.65% increase, with the full-year FY2025 number at $46.3 million, up 0.65% from a year prior.
  • Shares Outstanding (Weighted Average) hit $46.3 million in Q4 2025 for Avanos Medical, roughly flat from $46.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for AVNS hit a ceiling of $48.1 million in Q2 2021 and a floor of $46.0 million in Q3 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $46.8 million across 5 years, with a median of $46.6 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): fell 3.12% in 2022 and later increased 0.87% in 2025.
  • Tracing AVNS's Shares Outstanding (Weighted Average) over 5 years: stood at $48.1 million in 2021, then decreased by 2.49% to $46.9 million in 2022, then dropped by 0.64% to $46.6 million in 2023, then fell by 1.29% to $46.0 million in 2024, then rose by 0.65% to $46.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AVNS at $46.3 million in Q4 2025, $46.4 million in Q3 2025, and $46.3 million in Q2 2025.